Alnylam Pharmaceuticals (ALNY) Accounts Payables (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Accounts Payables data on file, last reported at $126.6 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 30.01% year-over-year to $126.6 million; the trailing twelve-month figure through Mar 2026 stood at $126.6 million (up 30.01% YoY), and the FY2025 full-year result was $115.7 million, up 30.88% from the prior year.
• Accounts Payables for Q1 2026 stood at $126.6 million, up from $115.7 million in the prior quarter.
• Across five years, Accounts Payables topped out at $126.6 million in Q1 2026 and bottomed at $40.6 million in Q3 2022.
• The 5-year median for Accounts Payables is $74.0 million (2024), against an average of $80.5 million.
• Peak annual rise in Accounts Payables reached 82.0% in 2023, while the deepest fall reached 43.4% in 2023.
• A 5-year view of Accounts Payables shows it stood at $98.1 million in 2022, then tumbled by 43.4% to $55.5 million in 2023, then jumped by 59.25% to $88.4 million in 2024, then jumped by 30.88% to $115.7 million in 2025, then increased by 9.43% to $126.6 million in 2026.
• The last three Accounts Payables figures came in at $126.6 million (Q1 2026), $115.7 million (Q4 2025), and $117.6 million (Q3 2025), per Business Quant data.

Peer Comparison